PT
PTN.US Palatin Technologies, Inc. Common Stock
- Market cap
- USD 9.55M
- P/E
- -
- P/B
- 1.63x
- ROE
- -998.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is PTN.US undervalued?
Graham numberThe Graham number of Palatin Technologies, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Palatin Technologies, Inc. Common Stock fundamental analysis
No fundamental analysis for Palatin Technologies, Inc. Common Stock yet.
Palatin Technologies, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 f…
Full company profilePalatin Technologies, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Palatin Technologies, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 44.7M | 67.1M | 60.3M | 118K | -189K | 1.47M | 4.85M | 4.49M | 0.00 | 13.2M | - |
| Gross Profit | 44.7M | 34.6M | 45.4M | 118K | -336K | 1.25M | 4.44M | 4.39M | -259K | 13.1M | - |
| Operating Income | -10.6M | 25.9M | 35.7M | -23.6M | -33.4M | -36.6M | -32.5M | -22.5M | -17.5M | -8.67M | -20.4M |
| EBITDA | -10.5M | 26.0M | 35.8M | -23.5M | -33.5M | -36.5M | -32.2M | -29.4M | -17.0M | -8.61M | -20.4M |
| Net Income | -13.3M | 24.7M | 35.8M | -22.4M | -33.6M | -35.8M | -27.5M | -29.7M | -17.3M | -8.38M | -20.2M |
| EPS | -1.81 | 2.98 | 4.12 | -2.38 | -3.55 | -3.75 | -2.53 | -2.02 | -32 | -2.96 | -5.16 |
| Balance Sheet | |||||||||||
| Total Assets | 56.8M | 39.0M | 105M | 85.1M | 67.3M | 36.1M | 17.9M | 10.7M | 3.27M | 8.52M | 4.72M |
| Total Liabilities | 62.0M | 12.1M | 4.19M | 4.88M | 17.6M | 19.8M | 19.9M | 10.9M | 8.04M | 1.84M | 2.69M |
| Shareholders' Equity | -5.16M | 27.0M | 101M | 80.2M | 49.7M | 16.3M | -1.98M | -111K | -4.78M | 6.69M | 2.03M |
| Cash & Short-term Investments | 40.5M | 38.0M | 43.5M | 82.9M | 60.1M | 29.9M | 11.0M | 9.53M | 2.56M | 7.49M | 3.74M |
| Total Debt | 14.1M | 6.28M | 333K | 1.27M | 1.25M | 1.15M | 1.05M | 590K | 164K | 224K | 160K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.9M | 1.70M | -21.8M | 41.3M | -22.6M | -29.9M | -28.4M | -31.5M | -21.3M | -13.5M | -15.0M |
| Capital Expenditure | 133K | 22.5K | 36.1K | 62.9K | 5.72K | 261K | 434K | 42.5K | 3.00 | 51.3K | 0.00 |
| Free Cash Flow | 12.7M | 1.68M | -21.8M | 41.3M | -22.7M | -30.2M | -28.9M | -31.5M | -21.3M | -13.6M | -15.0M |
| Ratios | |||||||||||
| ROE | - | 91.6% | 35.6% | -27.9% | -67.6% | -220.1% | - | - | - | -125.3% | -998.5% |
| ROA | -23.5% | 63.3% | 34.2% | -26.3% | -49.9% | -99.3% | -153.5% | -276.8% | -529.8% | -98.3% | -428.8% |
| Net Profit Margin | -29.8% | 36.8% | 59.3% | -18,969.5% | - | -2,438.5% | -567.4% | -662.3% | - | -63.5% | - |
| Debt to Equity | - | 0.23x | 0.00x | 0.02x | 0.03x | 0.07x | - | - | - | 0.03x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Palatin Technologies, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 146K | 0.01 | - |
| 2022 | USD 221K | 0.02 | - |
| 2021 | - | - | - |
| 2020 | USD 2.55M | 0.27 | - |
| 2019 | USD 116K | 0.01 | 0.3% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Aug 12, 2025.
Who owns Palatin Technologies, Inc. Common Stock
- Insiders 8.11%
- Institutions 59.16%
- Public & others 32.73%
- Shares outstanding 1.78M
- Free float 1.56M
Top funds holding PTN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 9.07K | 0.51% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 4.82K | 0.27% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 3.12K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.62K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.97K | 0.11% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.25K | 0.07% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 339.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding PTN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Driehaus Capital Management LLC | 167K | 9.36% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 140K | 7.86% | 0.00% | Jun 2026 |
| Logos Global Management LP | 130K | 7.30% | -7.14% | Jun 2026 |
| RA Capital Management, LLC | 62.1K | 3.49% | -11.25% | Jun 2026 |
| Balyasny Asset Management LLC | 41.1K | 2.31% | -0.14% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 27.3K | 1.53% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 20.5K | 1.15% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 19.4K | 1.09% | +4.76% | Jun 2026 |
| Vanguard Capital Management, LLC | 18.9K | 1.06% | -0.36% | Jun 2026 |
| Miller Financial Services LLC | 15.0K | 0.84% | +19.05% | Jun 2026 |
| LPL Financial Corp | 12.6K | 0.70% | -0.02% | Jun 2026 |
| Woodline Partners LP | 11.2K | 0.63% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 8.84K | 0.50% | +0.78% | Jun 2026 |
| BlackRock Inc | 5.65K | 0.32% | 0.00% | Jun 2026 |
| UBS Group AG | 2.99K | 0.17% | -10.30% | Jun 2026 |
| Vanguard Global Advisers, LLC | 1.25K | 0.07% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 593.00 | 0.03% | +75.44% | Jun 2026 |
| Advisor Group Holdings, Inc. | 170.00 | 0.01% | +0.59% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 155.00 | 0.01% | +3.33% | Jun 2026 |
| U.S. Bancorp | 125.00 | 0.01% | 0.00% | Jun 2026 |
Palatin Technologies, Inc. Common Stock company profile
- Company name
- Palatin Technologies, Inc. Common Stock
- Ticker
- PTN.US
- Exchange
- USA Stocks
- Listed since
- Oct 28, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- June
- Address
- 301 Carnegie Center Drive, Princeton, NJ, United States, 08540
- Phone
- 609 495 2200
- Website
- palatin.com
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Palatin Technologies, Inc. Common Stock management
7- Dr. Carl Spana Ph.D.Co-Founder, President, CEO & Director · born 1962
- Mr. Stephen T. Wills CPA, MSTCFO, COO, Executive VP, Treasurer & Secretary · born 1957
- Burns McClellanVice President of Investor Relations
- Mr. Stephen A. Slusher Esq.Chief Legal Officer
- Mr. James E. Hattersley B.A., M.S.Senior Vice President of Business Development · born 1960
- Mr. John Dodd Ph.D.Senior Vice President of Preclinical Development
- Mr. Robert JordanSenior Vice President of Program Operations